Neurocrine Biosciences rises 13.4% after earnings beat and raised INGREZZA guidance

What happened

Neurocrine Biosciences (NBIX) rose 13.4% on November 3, 2026, because third-quarter results beat estimates and the company raised INGREZZA guidance. The stock opened 9.4% above the previous close and closed at $164.85, with trading volume 3.3 times its 20-day average, according to Seeking Alpha and Zacks Investment Research. Those outlets reported quarterly EPS of $3.29 against $1.91 expected and that the company raised its 2026 INGREZZA net sales guidance to $2.9 to $2.925 billion.

How big was the move

The one-day move equaled 5.8 times a typical daily move for the stock and outpaced the Healthcare sector median on the day, which rose 0.6%, and the S&P 500, which rose 0.4%. Over the last five sessions the stock rose 12.9% while the S&P 500 over five sessions fell 2.0%, putting Neurocrine 12.8 percentage points better than the sector median. Market sensitivity remained muted: the stock has a beta of 0.61, meaning it tends to move less than the market.

The technical picture

Technically, the stock traded well above its short- and medium-term averages. It was 15.3% above its 20-day moving average, 12.4% above its 50-day moving average and 11.7% above its 200-day moving average. The 50-day average sat below the 200-day average, a sign of a weak longer-term trend. Momentum indicators showed the Relative Strength Index (14 days) at 76, a level often called overbought. The share price was 11.4% below its 52-week high. Over one month the stock rose 14.3%; over three months it rose 2.1%, and over one year it rose 15.1%, which was 4.5 percentage points ahead of the S&P 500. Sixty-day annualized volatility was 37%, higher than 76% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, Neurocrine reported revenue of $3.70 billion, a 38.0% increase from a year earlier and up from growth of 34.4% one quarter earlier. Diluted earnings per share for the period were $6.74, a rise of 61.2% from a year earlier. Gross margin stood at 97.8% versus 98.4% a year earlier, operating margin was 23.8% versus 20.5% a year earlier, and free-cash-flow margin was 28.1%. Return on invested capital was 13.2% and the balance sheet showed net cash of $249.2 million. Share count over one year increased by 2.6%.

Valuation measures showed the stock at 24.5 times trailing earnings and 23.1 times expected earnings, with a free-cash-flow yield of 7.0%. Its price to trailing earnings was lower than 86% of its own readings over the past five years, where the five-year median was 40.5 times earnings. The company’s market value was $14.85 billion on the session.

Earnings and analyst expectations

Neurocrine’s most recent quarterly report, issued November 2, 2026, showed EPS of $3.29 against $1.91 expected, 72.3% above estimates, and the company has beaten estimates for six consecutive quarters. The average surprise over the last four reports was 46.8% above estimates. Typical two-day share reaction after recent reports was to rise 0.4%, making the one-day 13.4% move on November 3 larger than its recent post-earnings responses. The next scheduled report date is February 10, 2027.

Analysts’ consensus rating was Buy, with 86% of the 37 analysts holding a Buy or Strong Buy rating. The consensus price target was $204.18, 23.9% above the closing price on November 3, 2026.

PromtFinance scores ranked Neurocrine strongly within the sector: Value 88 (Strong), Growth 92 (Exceptional), Quality 97 (Exceptional), Revisions 90 (Exceptional), Stability 91 (Exceptional) and Momentum 64 (Neutral).

What to watch

• November 2, 2026: quarterly EPS of $3.29 against $1.91 expected and raised INGREZZA 2026 net sales guidance to $2.9 to $2.925 billion.
• February 10, 2027: next scheduled earnings report.
• Consensus price target $204.18, 23.9% above the closing price, based on 37 analysts.
• Trading volume on November 3, 2026: 3.3 times its 20-day average.